These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19789217)

  • 21. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
    Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
    Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
    Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
    Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.
    Zhou Z; Guan H; Duan X; Kleinerman ES
    Cancer; 2005 Oct; 104(8):1713-20. PubMed ID: 16121404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.
    Neville-Webbe HL; Rostami-Hodjegan A; Evans CA; Coleman RE; Holen I
    Int J Cancer; 2005 Jan; 113(3):364-71. PubMed ID: 15455384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
    Hirbe AC; Roelofs AJ; Floyd DH; Deng H; Becker SN; Lanigan LG; Apicelli AJ; Xu Z; Prior JL; Eagleton MC; Piwnica-Worms D; Rogers MJ; Weilbaecher K
    Bone; 2009 May; 44(5):908-16. PubMed ID: 19442620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
    Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
    Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro.
    Neville-Webbe HL; Evans CA; Coleman RE; Holen I
    Tumour Biol; 2006; 27(2):92-103. PubMed ID: 16582586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ask us: Some drugs affect tooth movement.
    Schwartz JE
    Am J Orthod Dentofacial Orthop; 2005 Jun; 127(6):644. PubMed ID: 15968810
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
    Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G
    Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Green JR; Guenther A
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
    Mercatali L; Ricci M; Scarpi E; Serra P; Fabbri F; Ricci R; Liverani C; Zanoni M; Zoli W; Maltoni R; Gunelli E; Amadori D; Ibrahim T
    Int J Mol Sci; 2013 May; 14(6):10683-93. PubMed ID: 23702841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of BK(Ca) channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells.
    Ma YG; Liu WC; Dong S; Du C; Wang XJ; Li JS; Xie XP; Wu L; Ma DC; Yu ZB; Xie MJ
    PLoS One; 2012; 7(5):e37451. PubMed ID: 22655048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Zoledronic acid and bone pathology in the course of neoplasia. Part I].
    Caffo O
    Tumori; 2005; 91(5):22-6. PubMed ID: 16459649
    [No Abstract]   [Full Text] [Related]  

  • 34. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
    Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
    Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
    Coleman RE
    Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells.
    Rachner TD; Singh SK; Schoppet M; Benad P; Bornhäuser M; Ellenrieder V; Ebert R; Jakob F; Hofbauer LC
    Cancer Lett; 2010 Jan; 287(1):109-16. PubMed ID: 19577359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
    Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
    Zhao X; Xu X; Zhang Q; Jia Z; Sun S; Zhang J; Wang B; Wang Z; Hu X
    BMC Cancer; 2011 Sep; 11():403. PubMed ID: 21936956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.